Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions highlight the longstanding effectiveness of warfarin in stroke prevention, with references to meta-analyses and historical studies, emphasizing its continued relevance yet acknowledging challenges like adherence. The tone reflects both respect for the evidence and curiosity about its practical implications, demonstrating moderate engagement and perceived impact.
Most discussions acknowledge the findings that warfarin significantly reduces stroke risk, which aligns with established medical knowledge.
Participants show high interest in the topic, referencing historical data and discussing implications for practice.
Posts reference various aspects of the meta-analysis, such as methodological details and historical context, indicating moderate engagement.
The social discussions seem to recognize the significance of the research for clinical decision-making, but do not promote immediate changes in practice.
It's #ThrowbackThursday! This meta-analysis from the pre-DOAC era shows warfarin safely and effectively ⬇️ stroke risk vs aspirin in patients with non-valvular AF. Infographic by @rosko2860 from @UnmcCop ! #CardioTwitter #Cardiology Read it here: https://t.co/aLOsgJG5h6 https://t.co/JEFOA0sw71
ワルファリンは適切に管理されていれば安全性も高く、脳卒中もしくは全身性塞栓症リスクを6割ほど低下させる 。そのベネフィットは、出血リスクを考慮してもなお大きい 。 https://t.co/yGYq5Wmv0c https://t.co/mzLI1vDpkh https://t.co/d6JMQodyyp
13/15 Third point – what is the estimated risk reduction by using anticoagulation x placebo ? The best available data would be for the trials that compared warfarin x placebo. Again, going for meta-analysis data (https://t.co/LGWTOsLU7i) we have this figure: https://t.co/RZOrODVCnZ
5b) #Warfarin has been known to greatly attenuate #stroke risk for years (meta-analysis at https://t.co/NHPBcjWqcG), but for almost as long there has also been limited provider adherence to guidelines and patient compliance with warfarin.
3/15 The first point that crossed my mind when someone spoke at “intermediate” was the history of Aspirin for stroke prevention in Afib. Let’s that a look at that evidence – a meta-analysis published in 2007 by Hart and colleagues (https://t.co/LGWTOsLU7i)
RT @cardiomet_CE: 5b) #Warfarin has been known to greatly attenuate #stroke risk for years (meta-analysis at https://t.co/NHPBcjWqcG), but…
This meta-analysis of 29 trials involving over 28,000 patients shows that warfarin reduces stroke risk by about 60%, significantly more effective than antiplatelet agents, with minimal increase in bleeding risk.
This meta-analysis of 29 trials involving over 28,000 patients shows warfarin reduces stroke risk by 60%, outperforming antiplatelet agents which reduce risk by 20%. Minor bleeding risks are similar across treatments…
RT @accpcardprn: It's #ThrowbackThursday! This meta-analysis from the pre-DOAC era shows warfarin safely and effectively ⬇️ stroke risk vs…
RT @accpcardprn: It's #ThrowbackThursday! This meta-analysis from the pre-DOAC era shows warfarin safely and effectively ⬇️ stroke risk vs…
It's #ThrowbackThursday! This meta-analysis from the pre-DOAC era shows warfarin safely and effectively ⬇️ stroke risk vs aspirin in patients with non-valvular AF. Infographic by @rosko2860 from @UnmcCop ! #CardioTwitter #Cardiology Read it here: https://t.co/aLOsgJG5h6 https://t.co/JEFOA0sw71
RT @cardiomet_CE: 5b) #Warfarin has been known to greatly attenuate #stroke risk for years (meta-analysis at https://t.co/NHPBcjWqcG), but…
5b) #Warfarin has been known to greatly attenuate #stroke risk for years (meta-analysis at https://t.co/NHPBcjWqcG), but for almost as long there has also been limited provider adherence to guidelines and patient compliance with warfarin.
ワルファリンは適切に管理されていれば安全性も高く、脳卒中もしくは全身性塞栓症リスクを6割ほど低下させる 。そのベネフィットは、出血リスクを考慮してもなお大きい 。 https://t.co/yGYq5Wmv0c https://t.co/mzLI1vDpkh https://t.co/d6JMQodyyp
13/15 Third point – what is the estimated risk reduction by using anticoagulation x placebo ? The best available data would be for the trials that compared warfarin x placebo. Again, going for meta-analysis data (https://t.co/LGWTOsLU7i) we have this figure: https://t.co/RZOrODVCnZ
3/15 The first point that crossed my mind when someone spoke at “intermediate” was the history of Aspirin for stroke prevention in Afib. Let’s that a look at that evidence – a meta-analysis published in 2007 by Hart and colleagues (https://t.co/LGWTOsLU7i)